| symbol |
GWPH |
|---|
| 会社名 | GW Pharmaceuticals Plc （GWファ―マシュ―ティカルズ） |
|---|
| 分野（sector） |
Health Care
ヘルスケア
|
|---|
| 産業（industry） |
Major Pharmaceuticals
|
|---|
| 業種 |
バイオテクノロジ―_メディカルリサ―チ
医療関連（Health Care）
|
|---|
| 概要 |
事業概要 GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols) which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial Sativex Research and Development and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform. GWファ―マシュ―ティカルズは英国のバイオ医薬品会社。色々な疾病の治療薬として、独自のカンナビノイド製品発見、開発、商業化に従事。同社の主要医薬品｢サティベックス｣を多発性硬化症、がんの痛み、神経痛の痛みを緩和させる口腔粘膜スプレ―治療薬として研究、開発中。
|
|---|
| 本社所在地 | Sovereign House Vision Park Chivers Way Histon Cambridge CB24 9BZ GBR |
|---|
| 代表者氏名 | Geoffrey W. Guy ジェフリーW.ガイ |
|---|
| 代表者役職名 | Executive Chairman of the Board 取締役会長 |
|---|
| 電話番号 | +44 1223-26-6800 |
|---|
| 設立年月日 | 1998年 |
|---|
| 市場名 | NASDAQ National Market System |
|---|
| ipoyear | 2013年 |
|---|
| 従業員数 | 583人 |
|---|
| url | www.gwpharm.com |
|---|
| nasdaq_url | https://www.nasdaq.com/symbol/gwph |
|---|
| adr_tso | 26599036 |
|---|
| EBITDA | EBITDA（百万ドル） -219.66910 |
|---|
| 終値（lastsale） | 146.07 |
|---|
| 時価総額（marketcap） | 3885321188.52 |
|---|
| 時価総額 | 時価総額（百万ドル） 3959.721 |
|---|
| 売上高 | 売上高（百万ドル） 16.56232 |
|---|
| 企業価値(EV) | 企業価値(EV)（百万ドル） 3512.80622 |
|---|
| 当期純利益 | 当期純利益（百万ドル） -250.08300 |
|---|
| 決算概要 | 決算概要 BRIEF: For the six months ended 31 March 2018 GW Pharmaceuticals PLC- ADR revenues increased from ￡3.7M to ￡8.1M. Net loss increased from ￡50M to ￡109.6M. Revenues reflect Europe (Excluding UK) segment increase of 60% to ￡1.6M Canada segment increase from ￡0K to ￡196K. Higher net loss reflects Net foreign exchange (loss)/gain increase from ￡7.8M (income) to ￡17.2M (expense) Selling/General/Admin. |
|---|